Synopsis
Synopsis
0
CEP/COS
0
KDMF
0
VMF
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Methyllorazepam
1. Methyllorazepam
2. N-methyllorazepam
3. Noctamid
4. Loramet
5. 848-75-9
6. Lormetazepamum
7. Chlorotemazepam
8. Ergocalm
9. Noctamide
10. Wy-4082
11. Loramet (tn)
12. 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-1-methyl-2h-1,4-benzodiazepin-2-one
13. Ro 5-5516
14. Wy 4082
15. 7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-1-methyl-2h-1,4-benzodiazepin-2-one
16. 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-2,3-dihydro-1h-1,4-benzodiazepin-2-one
17. 2h-1,4-benzodiazepin-2-one, 7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-1-methyl-
18. 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-3h-1,4-benzodiazepin-2-one
19. Chembl22097
20. Gu56c842za
21. Chebi:52993
22. 2h-1,4-benzodiazepin-2-one, 1,3-dihydro-7-chloro-5-(o-chlorophenyl)-3-hydroxy-1-methyl-
23. 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-1,3-dihydro-2h-1,4-benzodiazepin-2-one
24. Lormetazepamum [inn-latin]
25. (rs)-lormetazepam
26. (+/-)-lormetazepam
27. Lormetazepam [usan:inn:ban:jan]
28. Einecs 212-700-5
29. Brn 0759821
30. Unii-gu56c842za
31. Loretam
32. Dea No. 2774
33. ()-lorazepam
34. (+-)-lorazepam
35. Lormetazepam [mi]
36. Lormetazepam [inn]
37. Lormetazepam [jan]
38. Lormetazepam [usan]
39. Schembl43267
40. Lormetazepam [mart.]
41. Lormetazepam [who-dd]
42. Gtpl7553
43. Lormetazepam (jan/usan/inn)
44. Dtxsid40862442
45. Lormetazepam 0.1 Mg/ml In Methanol
46. Lormetazepam 1.0 Mg/ml In Methanol
47. Ortho-chloro-3-hydroxydiazepam
48. Db13872
49. Zk-65997
50. D01657
51. Q186257
52. 7-chloro-1,3-dihydro-5-(o-chlorophenyl)-3-hydroxy-1-methyl-2h-1,4-benzodiazepin-2-one
53. 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-1,3-dihydro-2h-1,4-benzodiazepin-2-one #
54. Lormetazepam Solution, 1.0 Mg/ml In Methanol, Ampule Of 1 Ml, Certified Reference Material
Molecular Weight | 335.2 g/mol |
---|---|
Molecular Formula | C16H12Cl2N2O2 |
XLogP3 | 2.4 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 1 |
Exact Mass | 334.0275830 g/mol |
Monoisotopic Mass | 334.0275830 g/mol |
Topological Polar Surface Area | 52.9 Ų |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 471 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
For the treatment of short-term insomnia
Lormetazepam is a benzodiazepine which reduces central nervous system (CNS) activity. It produces anxiolytic, muscle relaxant, sedative and hypnotic effects. Because it is a short-acting benzodiapine, it does not produce significant sedation after waking.
Hypnotics and Sedatives
Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. (See all compounds classified as Hypnotics and Sedatives.)
N05CD06
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
N - Nervous system
N05 - Psycholeptics
N05C - Hypnotics and sedatives
N05CD - Benzodiazepine derivatives
N05CD06 - Lormetazepam
Metabolised to an inactive metabolite via glucuronide conjugation
The terminal phase half life is 11 h.
Lormetazepam, as a benzodiazepine, binds to the regulatory site between the and subunits of -aminobutryic acid (GABA) A receptors with 2 and 1, 2, 3, or 5 subunits. This facilitates the opening of the chloride channel allowing chloride ions to flow into the neuron resulting in hyperpolarization. Hyperpolarized neurons require greater simulation to reach their action potential threshold. The general inhibitory effect on neuronal depolarization produces the effects of lormetazepam.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
ABOUT THIS PAGE
A Lormetazepam manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lormetazepam, including repackagers and relabelers. The FDA regulates Lormetazepam manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lormetazepam API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Lormetazepam manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Lormetazepam supplier is an individual or a company that provides Lormetazepam active pharmaceutical ingredient (API) or Lormetazepam finished formulations upon request. The Lormetazepam suppliers may include Lormetazepam API manufacturers, exporters, distributors and traders.
click here to find a list of Lormetazepam suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Lormetazepam DMF (Drug Master File) is a document detailing the whole manufacturing process of Lormetazepam active pharmaceutical ingredient (API) in detail. Different forms of Lormetazepam DMFs exist exist since differing nations have different regulations, such as Lormetazepam USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Lormetazepam DMF submitted to regulatory agencies in the US is known as a USDMF. Lormetazepam USDMF includes data on Lormetazepam's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lormetazepam USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Lormetazepam suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Lormetazepam Drug Master File in Japan (Lormetazepam JDMF) empowers Lormetazepam API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Lormetazepam JDMF during the approval evaluation for pharmaceutical products. At the time of Lormetazepam JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Lormetazepam suppliers with JDMF on PharmaCompass.
A Lormetazepam written confirmation (Lormetazepam WC) is an official document issued by a regulatory agency to a Lormetazepam manufacturer, verifying that the manufacturing facility of a Lormetazepam active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Lormetazepam APIs or Lormetazepam finished pharmaceutical products to another nation, regulatory agencies frequently require a Lormetazepam WC (written confirmation) as part of the regulatory process.
click here to find a list of Lormetazepam suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Lormetazepam as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Lormetazepam API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Lormetazepam as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Lormetazepam and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Lormetazepam NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Lormetazepam suppliers with NDC on PharmaCompass.
Lormetazepam Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lormetazepam GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lormetazepam GMP manufacturer or Lormetazepam GMP API supplier for your needs.
A Lormetazepam CoA (Certificate of Analysis) is a formal document that attests to Lormetazepam's compliance with Lormetazepam specifications and serves as a tool for batch-level quality control.
Lormetazepam CoA mostly includes findings from lab analyses of a specific batch. For each Lormetazepam CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lormetazepam may be tested according to a variety of international standards, such as European Pharmacopoeia (Lormetazepam EP), Lormetazepam JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lormetazepam USP).
LOOKING FOR A SUPPLIER?